Oncology and Hematology

129-144 of 189

• 

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  MinuteCE®

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  MinuteCE®

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  Susana Campos, MD, MPH; Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  Susana Campos, MD, MPH; Ritu Salani, MD, MBA

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  MinuteCE®

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  Susana Campos, MD, MPH; Ritu Salani, MD, MBA

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  Nicoletta Colombo, MD; Ritu Salani, MD, MBA

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 credits 10 episodes

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  Ignacio Duran, MD; Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  MinuteCE®

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  Nicoletta Colombo, MD; Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  MinuteCE®

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  MinuteCE®

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  MinuteCE®

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 credit 10 episodes

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 credit 10 episodes

• Previous
• 1
• 2
• …
• 7
• 8
• 9
• 10
• 11
• 12
• Next